← ANALYST RATINGS · TIPRANKS
PepGen Inc. (PEPG): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $16.00, the highest $20.00, the lowest $12.00. The average is +515.4% from the last price of $2.60.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $12.00 | Buy | +361.5% | Reiterated | 08.10.26on TipRanks 09:05 | −0.4%next day +9.5% · 5 days +6.6% | ↗ |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $15.00 | Buy | +476.9% | Reiterated | 07.10.26on TipRanks Oct 8 06:00 | +4.1%next day −0.4% · 5 days −2.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 | Hold | −3.8% | Reiterated | 30.09.26on TipRanks 18:09 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 | Hold | −3.8% | Reiterated | 30.09.26on TipRanks 18:09 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 | Hold | −3.8% | Reiterated | 30.09.26on TipRanks 18:09 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 | Hold | −3.8% | Reiterated | 30.09.26on TipRanks 18:09 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 | Hold | −3.8% | Reiterated | 30.09.26on TipRanks 18:09 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | −23.1% | Reiterated | 30.09.26on TipRanks 18:09 | — | |
| Unknown Analyst | Leerink Partners | $10.00 | Buy | +284.6% | Reiterated | 18.09.26on TipRanks Sep 24 21:02 | −4.2%next day −1.9% · 5 days −10.4% | ↗ |
| Ananda Ghosh★★★★★★★★★★#1171 · hits 53% · avg +20.8% | H.C. Wainwright | $20.00 | Buy | +669.2% | Reiterated | 09.09.26on TipRanks 06:45 | −1.4%next day −3.5% · 5 days −6.8% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $3.00 → $2.50−16.7% | Sell | −3.8% | Reiterated | 07.08.26on TipRanks 06:50 | +17.6%next day +4.9% · 5 days +4.5% | ↗ |
| Adam Vogel★★★★★★★★★★#1113 · hits 79% · avg +38.0% | Craig-Hallum | $11.00 | Buy | +323.1% | Reiterated | 06.08.26on TipRanks 09:35 | +21.9%next day +17.6% · 5 days +22.4% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $7.00 | Buy | +169.2% | Reiterated | 08.06.26on TipRanks Jul 1 20:45 | −4.5%next day +2.5% · 5 days +11.2% | |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $5.00 → $4.00−20.0% | Buy | +53.8% | Reiterated | 13.05.26on TipRanks 08:35 | +5.4%next day −8.1% · 5 days −19.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering PepGen Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 08.10.26: target $11.75 at a price of $2.40 (+389.6%); now: $11.75 at $2.60 (+351.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 3 | 2 | 2 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About PepGen Inc.
- CEO: James McArthur
- Employees: 57
- 321 Harrison Avenue, Boston, MA, 02118, US
- www.pepgen.com
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 39 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗